Recurrent Energy Announces Initial Closing of Investment from BlackRock
Corbus Pharmaceuticals Holdings Inc.
SYS6002 (CRB-701) A Next Generation Nectin-4 Targeting Antibody Drug[...]
Beyond Cancer Presents First in Class Clinical Data Showing an[...]
05/09/2024 | Press release | Distributed by Public on 05/09/2024 16:30
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact